Silo pharma's sp-26 ketamine implant meets all endpoints in fibromyalgia study

— successfully demonstrates strong tolerability, sustained drug release and safety sarasota, fl, april 30, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo,” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating sp-26, a novel extended-release ketamine implant which it believes supports sp-26's potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia. all study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation.
SILO Ratings Summary
SILO Quant Ranking